✦ LIBER ✦

Incorrect cost of infliximab in Crohn’s disease

✍ Scribed by Gary R. Lichtenstein

Book ID: 119757953
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 71 KB
Volume: 127
Category: Article
ISSN: 0016-5085
DOI: 10.1053/j.gastro.2004.06.043

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Individualised infliximab therapy saves

Individualised infliximab therapy saves costs in Crohn's disease

✍ Dvurečenskij, Anatolij; Xie, Yongjian; Yang, Aili 📂 Article 📅 2013 🏛 Adis International Limited (now part of Wolters Kl ⚖ 115 KB

Infliximab reduces resource use and cost

Infliximab reduces resource use and costs in Crohn's disease

📂 Article 📅 2013 🏛 Adis International Limited (now part of Wolters Kl ⚖ 111 KB

Infliximab for Crohn's disease perianal

Infliximab for Crohn's disease perianal fistulae worth its cost?

📂 Article 📅 2001 🏛 Adis International Limited (now part of Wolters Kl ⚖ 139 KB

Infliximab in Fistulizing Crohn's Diseas

Infliximab in Fistulizing Crohn's Disease

✍ Osterman, Mark T.; Lichtenstein, Gary R. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 225 KB

Immunogenicity of Infliximab in Crohn's

Immunogenicity of Infliximab in Crohn's Disease

📂 Article 📅 2003 🏛 Massachusetts Medical Society 🌐 English ⚖ 66 KB

Infliximab dose intensification in Crohn

Infliximab dose intensification in Crohn's disease

✍ Miguel Regueiro; Benjamin Siemanowski; Kevin E. Kip; Scott Plevy 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 176 KB 👁 1 views

Background: Crohn's disease (CD) patients who lose response to infliximab may benefit from an increase in dose or decrease in interval between infusions. The aims of this study were to determine the proportion of CD patients who require dose intensification and factors associated with dose intensifi